# OnCo record haystack-mrd (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/haystack-mrd/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "haystack-mrd" ;
  schema:name "Haystack MRD"@en ;
  schema:description "Quest Diagnostics' blood test for leftover cancer after surgery, with an FDA Breakthrough Device designation in stage II bowel cancer."@en ;
  schema:url <https://onco.cc/drugs/haystack-mrd/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://haystackmrd.com/>, <https://haystackmrd.com/clinicians/>, <https://haystackmrd.com/fda-grants-breakthrough-device-designation-for-haystack-mrd-circulating-tumor-dna-test-from-quest-diagnostics/>, <https://haystackmrd.com/haystack-mrd-receives-new-york-state-approval/>, <https://newsroom.questdiagnostics.com/2023-06-21-Quest-Diagnostics-Completes-Acquisition-of-Haystack-Oncology,-Adding-Sensitive-MRD-Liquid-Biopsy-Technology-to-Cancer-Diagnostics-Portfolio> ;
  onco:status "emerging" ;
  onco:tag "test" ;
  onco:modality "Tumour-informed ctDNA minimal residual disease test (up to 50 variants)" ;
  schema:alternateName "Haystack MRD" ;
  onco:related <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/radar-mrd/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:companies <https://onco.cc/companies/haystack-oncology/>, <https://onco.cc/companies/quest-diagnostics/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:trials <https://onco.cc/trials/dynamic/> .